1-3 of 3
Yali Wang
Close
Sort by
Journal Articles

Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Feng Xue, Hu Zhou, Yun Chen, Jing Sun, Xiaojing Zeng, Chenghao Jin, Pingchong Lei, Zhenyu Li, Yaming Xi, Lirong Sun, Zhongguang Cui, Xielan Zhao, Linhua Yang, Bangshuo Zhang, Aizong Shen, Runhui Wu, Xiaolin Wang, Ling Liu, Yuhua Wang, Lizhi Sun, Yan Xia, Weichuan Mo, Dong Yuan, Jiwei Lou, Taiping Gan, Chengli Hu, Chen Ling, Hongsheng Su, Yali Wang, Baolin Tang, Renchi Yang
Journal: Blood
Blood (2022) 140 (Supplement 1): 8468–8469.
https://doi.org/10.1182/blood-2022-158760
Published: 2022
Journal Articles

Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients

Feng Xue, MD, Jing Sun, MD, Yun Chen, MD, Xinsheng Zhang, MD, Haiyan Sun, MD, Yali Wang, PhD, Renchi Yang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4932.
https://doi.org/10.1182/blood-2019-128600
Published: 2019
Journal Articles

Development of a Pegylated Dimeric Recombinant Factor VIII-Fc Fusion Protein for the Treatment for Hemophilia a Patients

Bin Liu, PhD, Xiaoshan Wang, Master, Xueqin Li, Master, Haixia Yan, PhD, Shuya Wang, Master, Xi Zhu, Pengju Wang, Jie Gao, Master, Yali Wang, PhD, Hongsheng Su, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3783.
https://doi.org/10.1182/blood-2018-99-112030
Published: 2018